Bim and Mcl-1 exert key roles in regulating JAK2V617F cell survival

BMC Cancer

Volumn 11, Issue , 2011, Pages

  Rubert, Joëlle ^a   Qian, Zhiyan ^a   Andraos, Rita ^a   Guthy, Daniel A ^a   Radimerski, Thomas ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

BIM PROTEIN; JANUS KINASE 2; JANUS KINASE 2 INHIBITOR; NVP BSK 805; PHENYLALANINE; PROTEIN BCL XL; PROTEIN MCL 1; SMALL INTERFERING RNA; STAT5 PROTEIN; UNCLASSIFIED DRUG; VALINE; APOPTOSIS REGULATORY PROTEIN; BCL 2 LIKE PROTEIN 11; BCL-2-LIKE PROTEIN 11; CASPASE; JAK2 PROTEIN, HUMAN; MEMBRANE PROTEIN; MYELOID CELL LEUKEMIA SEQUENCE 1 PROTEIN; NVP BSK805; NVP-BSK805; ONCOPROTEIN; PROTEIN BCL 2; QUINOXALINE DERIVATIVE;

APOPTOSIS; ARTICLE; CELL DEATH; CELL PROLIFERATION; CELL SURVIVAL; CELL VIABILITY; CONTROLLED STUDY; DRUG EFFECT; ENZYME INHIBITION; GENE MUTATION; MUTANT; PROTEIN FUNCTION; RNA INTERFERENCE; SIGNAL TRANSDUCTION; AMINO ACID SUBSTITUTION; CELL LINE; DRUG ANTAGONISM; FLOW CYTOMETRY; GENETICS; HUMAN; METABOLISM; MUTATION; PHOSPHORYLATION; PHYSIOLOGY; TUMOR CELL LINE; WESTERN BLOTTING;

AMINO ACID SUBSTITUTION; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; BLOTTING, WESTERN; CASPASES; CELL LINE; CELL LINE, TUMOR; CELL SURVIVAL; FLOW CYTOMETRY; HUMANS; JANUS KINASE 2; MEMBRANE PROTEINS; MUTATION; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-BCL-2; QUINOXALINES; RNA INTERFERENCE; SIGNAL TRANSDUCTION;

EID: 78651515826     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-11-24     Document Type: Article

References (56)

1. Nelson ME, Steensma DP. JAK2 V617F in myeloid disorders: What do we know now, and where are we headed?. Leuk Lymphoma 2006, 47:177-194. 10.1080/10428190500301348, 16321848.
2. Saharinen P, Vihinen M, Silvennoinen O. Autoinhibition of Jak2 Tyrosine Kinase Is Dependent on Specific Regions in Its Pseudokinase Domain. Mol Biol Cell 2003, 14:1448-1459. 10.1091/mbc.E02-06-0342, 153113, 12686600.
3. Levine RL, Wadleigh M, Cools J, Ebert BL, Wernig G, Huntly BJP, Boggon TJ, Wlodarska I, Clark JJ, Moore S, et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 2005, 7:387-397. 10.1016/j.ccr.2005.03.023, 15837627.
4. Vannucchi AM. How do JAK2-inhibitors work in myelofibrosis: An alternative hypothesis. Leukemia Res 2009, 33:1581-1583.
5. Mesa R, Gale RP. Hypothesis: How do JAK2-inhibitors work in myelofibrosis. Leukemia Res 2009, 33:1156-1157.
6. Jamieson CH, Gotlib J, Durocher JA, Chao MP, Mariappan MR, Lay M, Jones C, Zehnder JL, Lilleberg SL, Weissman IL. The JAK2 V617F mutation occurs in hematopoietic stem cells in polycythemia vera and predisposes toward erythroid differentiation. Proc Natl Acad Sci USA 2006, 103:6224-6229. 10.1073/pnas.0601462103, 1434515, 16603627.
7. Laubach JP, Fu P, Jiang X, Salter KH, Potti A, Arcasoy MO. Polycythemia vera erythroid precursors exhibit increased proliferation and apoptosis resistance associated with abnormal RAS and PI3K pathway activation. Exp Hematol 2009, 37:1411-1422. 10.1016/j.exphem.2009.09.009, 2783925, 19815050.
8. Silva M, Richard C, Benito A, Sanz C, Olalla I, Fernandez-Luna JL. Expression of Bcl-x in Erythroid Precursors from Patients with Polycythemia Vera. N Engl J Med 1998, 338:564-571. 10.1056/NEJM199802263380902, 9475763.
9. Zeuner A, Pedini F, Francescangeli F, Signore M, Girelli G, Tafuri A, De Maria R. Activity of the BH3 mimetic ABT-737 on polycythemia vera erythroid precursor cells. Blood 2009, 113:1522-1525. 10.1182/blood-2008-03-143321, 19060244.
10. Gozgit JM, Bebernitz G, Patil P, Ye M, Parmentier J, Wu J, Su N, Wang T, Ioannidis S, Davies A, et al. Effects of the JAK2 Inhibitor, AZ960, on Pim/BAD/BCL-xL Survival Signaling in the Human JAK2 V617F Cell Line SET-2. J Biol Chem 2008, 283:32334-32343. 10.1074/jbc.M803813200, 18775810.
11. Adams JM, Cory S. The Bcl-2 apoptotic switch in cancer development and therapy. Oncogene 2007, 26:1324-1337. 10.1038/sj.onc.1210220, 2930981, 17322918.
12. Zhang B, Gojo I, Fenton RG. Myeloid cell factor-1 is a critical survival factor for multiple myeloma. Blood 2002, 99:1885-1893. 10.1182/blood.V99.6.1885, 11877256.
13. Kaufmann SH, Karp JE, Svingen PA, Krajewski S, Burke PJ, Gore SD, Reed JC. Elevated Expression of the Apoptotic Regulator Mcl-1 at the Time of Leukemic Relapse. Blood 1998, 91:991-1000.
14. Pissot-Soldermann C, Gerspacher M, Furet P, Gaul C, Holzer P, McCarthy C, Radimerski T, Regnier CH, Baffert F, Drueckes P, et al. Discovery and SAR of potent, orally available 2,8-diaryl-quinoxalines as a new class of JAK2 inhibitors. Bioorg Med Chem Lett 2010, 20:2609-2613. 10.1016/j.bmcl.2010.02.056, 20231096.
15. Gomez-Bougie P, Bataille R, Amiot M. The imbalance between Bim and Mcl-1 expression controls the survival of human myeloma cells. Eur J Immunol 2004, 34:3156-3164. 10.1002/eji.200424981, 15459900.
16. Ewings KE, Hadfield-Moorhouse K, Wiggins CM, Wickenden JA, Balmanno K, Gilley R, Degenhardt K, White E, Cook SJ. ERK1/2-dependent phosphorylation of BimEL promotes its rapid dissociation from Mcl-1 and Bcl-xL. EMBO J 2007, 26:2856-2867. 10.1038/sj.emboj.7601723, 1894764, 17525735.
17. Baffert F, Régnier CH, De Pover A, Pissot-Soldermann C, Tavares GA, Blasco F, Brueggen J, Chène P, Drueckes P, Erdmann D, et al. Potent and Selective Inhibition of Polycythemia by the Quinoxaline JAK2 Inhibitor NVP-BSK805. Mol Cancer Ther 2010, 9:1945-1955. 10.1158/1535-7163.MCT-10-0053, 20587663.
18. Uozumi K, Otsuka M, Ohno N, Moriyama T, Suzuki S, Shimotakahara S, Matsumura I, Hanada S, Arima T. Establishment and characterization of a new human megakaryoblastic cell line (SET-2) that spontaneously matures to megakaryocytes and produces platelet-like particles. Leukemia 2000, 14:142-152. 10.1038/sj.leu.2401608, 10637490.
19. Morgan DA, Gumucio DL, Brodsky I. Granulocyte-macrophage colony-stimulating factor-dependent growth and erythropoietin-induced differentiation of a human cell line MB-02. Blood 1991, 78:2860-2871.
20. Adams JM. Ways of dying: multiple pathways to apoptosis. Genes Dev 2003, 17:2481-2495. 10.1101/gad.1126903, 14561771.
21. Will B, Siddiqi T, Jorda MA, Shimamura T, Luptakova K, Staber PB, Costa DB, Steidl U, Tenen DG, Kobayashi S. Apoptosis induced by JAK2 inhibition is mediated by Bim and enhanced by the BH3 mimetic ABT-737 in JAK2 mutant human erythroid cells. Blood 2010, 115:2901-2909. 10.1182/blood-2009-03-209544, 20160166.
22. Chao J-R, Wang J-M, Lee S-F, Peng H-W, Lin Y-H, Chou C-H, Li J-C, Huang H-M, Chou C-K, Kuo M-L, et al. mcl-1 Is an Immediate-Early Gene Activated by the Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) Signaling Pathway and Is One Component of the GM-CSF Viability Response. Mol Cell Biol 1998, 18:4883-4898. 109073, 9671497.
23. Maurer U, Charvet C, Wagman AS, Dejardin E, Green DR. Glycogen Synthase Kinase-3 Regulates Mitochondrial Outer Membrane Permeabilization and Apoptosis by Destabilization of MCL-1. Mol Cell 2006, 21:749-760. 10.1016/j.molcel.2006.02.009, 16543145.
24. Zhong Q, Gao W, Du F, Wang X. Mule/ARF-BP1, a BH3-Only E3 Ubiquitin Ligase, Catalyzes the Polyubiquitination of Mcl-1 and Regulates Apoptosis. Cell 2005, 121:1085-1095. 10.1016/j.cell.2005.06.009, 15989957.
25. Moulding DA, Quayle JA, Hart CA, Edwards SW. Mcl-1 Expression in Human Neutrophils: Regulation by Cytokines and Correlation With Cell Survival. Blood 1998, 92:2495-2502.
26. Harada H, Quearry B, Ruiz-Vela A, Korsmeyer SJ. Survival factor-induced extracellular signal-regulated kinase phosphorylates BIM, inhibiting its association with BAX and proapoptotic activity. Proc Natl Acad Sci USA 2004, 101:15313-15317. 10.1073/pnas.0406837101, 524459, 15486085.
27. Garcon L, Rivat C, James C, Lacout C, Camara-Clayette V, Ugo V, Lecluse Y, Bennaceur-Griscelli A, Vainchenker W. Constitutive activation of STAT5 and Bcl-xL overexpression can induce endogenous erythroid colony formation in human primary cells. Blood 2006, 108:1551-1554. 10.1182/blood-2005-10-009514, 16684963.
28. Zhao R, Follows GA, Beer PA, Scott LM, Huntly BJP, Green AR, Alexander DR. Inhibition of the Bcl-xL Deamidation Pathway in Myeloproliferative Disorders. N Engl J Med 2008, 359:2778-2789. 10.1056/NEJMoa0804953, 19109573.
29. Willis SN, Chen L, Dewson G, Wei A, Naik E, Fletcher JI, Adams JM, Huang DCS. Proapoptotic Bak is sequestered by Mcl-1 and Bcl-xL, but not Bcl-2, until displaced by BH3-only proteins. Genes Dev 2005, 19:1294-1305. 10.1101/gad.1304105, 1142553, 15901672.
30. Luciano F, Jacquel A, Colosetti P, Herrant M, Cagnol S, Pages G, Auberger P. Phosphorylation of Bim-EL by Erk1//2 on serine 69 promotes its degradation via the proteasome pathway and regulates its proapoptotic function. Oncogene 2003, 22:6785-6793. 10.1038/sj.onc.1206792, 14555991.
31. Wiggins CM, Band H, Cook SJ. c-Cbl is not required for ERK1/2-dependent degradation of BimEL. Cell Signal 2007, 19:2605-2611. 10.1016/j.cellsig.2007.08.008, 2707770, 17884340.
32. Nguyen M, Marcellus RC, Roulston A, Watson M, Serfass L, Murthy Madiraju SR, Goulet D, Viallet J, Bélec L, Billot X, et al. Small molecule obatoclax (GX15-070) antagonizes MCL-1 and overcomes MCL-1-mediated resistance to apoptosis. Proc Natl Acad Sci USA 2007, 104:19512-19517. 10.1073/pnas.0709443104, 2148320, 18040043.
33. Tse C, Shoemaker AR, Adickes J, Anderson MG, Chen J, Jin S, Johnson EF, Marsh KC, Mitten MJ, Nimmer P, et al. ABT-263: A Potent and Orally Bioavailable Bcl-2 Family Inhibitor. Cancer Res 2008, 68:3421-3428. 10.1158/0008-5472.CAN-07-5836, 18451170.
34. Bouillet P, Metcalf D, Huang DC, Tarlinton DM, Kay TW, Köntgen F, Adams JM, Strasser A. Proapoptotic Bcl-2 Relative Bim Required for Certain Apoptotic Responses, Leukocyte Homeostasis, and to Preclude Autoimmunity. Science 1999, 286:1735-1738. 10.1126/science.286.5445.1735, 10576740.
35. Abutin RM, Chen J, Lung TK, Lloyd JA, Sawyer ST, Harada H. Erythropoietin-induced phosphorylation/degradation of BIM contributes to survival of erythroid cells. Exp Hematol 2009, 37:151-158. 10.1016/j.exphem.2008.10.008, 2656114, 19100675.
36. Dijkers PF, Medema RH, Lammers J-W, Koenderman L, Coffer PJ. Expression of the pro-apoptotic Bcl-2 family member Bim is regulated by the forkhead transcription factor FKHR-L1. Curr Biol 2000, 10:1201-1204. 10.1016/S0960-9822(00)00728-4, 11050388.
37. Essafi A, Fernandez de Mattos S, Hassen YAM, Soeiro I, Mufti GJ, Thomas NSB, Medema RH, Lam EWF. Direct transcriptional regulation of Bim by FoxO3a mediates STI571-induced apoptosis in Bcr-Abl-expressing cells. Oncogene 2005, 24:2317-2329. 10.1038/sj.onc.1208421, 15688014.
38. Maeda T, Ito K, Merghoub T, Poliseno L, Hobbs RM, Wang G, Dong L, Maeda M, Dore LC, Zelent A, et al. LRF Is an Essential Downstream Target of GATA1 in Erythroid Development and Regulates BIM-Dependent Apoptosis. Dev Cell 2009, 17:527-540. 10.1016/j.devcel.2009.09.005, 19853566.
39. Gélinas C, White E. BH3-only proteins in control: specificity regulates MCL-1 and BAK-mediated apoptosis. Genes Dev 2005, 19:1263-1268.
40. Opferman JT, Iwasaki H, Ong CC, Suh H, Mizuno S, Akashi K, Korsmeyer SJ. Obligate Role of Anti-Apoptotic MCL-1 in the Survival of Hematopoietic Stem Cells. Science 2005, 307:1101-1104. 10.1126/science.1106114, 15718471.
41. Motoyama N, Wang F, Roth KA, Sawa H, Nakayama K, Nakayama K, Negishi I, Senju S, Zhang Q, Fujii S, Loh DY. Massive cell death of immature hematopoietic cells and neurons in Bcl-x-deficient mice. Science 1995, 267:1506-1510. 10.1126/science.7878471, 7878471.
42. Wagner KU, Claudio E, Rucker EB, Riedlinger G, Broussard C, Schwartzberg PL, Siebenlist U, Hennighausen L. Conditional deletion of the Bcl-x gene from erythroid cells results in hemolytic anemia and profound splenomegaly. Development 2000, 127:4949-4958.
43. Richmond TD, Chohan M, Barber DL. Turning cells red: signal transduction mediated by erythropoietin. Trends Cell Biol 2005, 15:146-155. 10.1016/j.tcb.2005.01.007, 15752978.
44. Quelle FW, Wang J, Feng J, Wang D, Cleveland JL, Ihle JN, Zambetti GP. Cytokine rescue of p53-dependent apoptosis and cell cycle arrest is mediated by distinct Jak kinase signaling pathways. Genes Dev 1998, 12:1099-1107. 10.1101/gad.12.8.1099, 316716, 9553040.
45. Puthier D, Bataille R, Amiot M. IL-6 up-regulates Mcl-1 in human myeloma cells through JAK/STAT rather than Ras/MAP kinase pathway. Eur J Immunol 1999, 29:3945-3950. 10.1002/(SICI)1521-4141(199912)29:12<3945::AID-IMMU3945>3.0.CO;2-O, 10602002.
46. Kuribara R, Honda H, Matsui H, Shinjyo T, Inukai T, Sugita K, Nakazawa S, Hirai H, Ozawa K, Inaba T. Roles of Bim in Apoptosis of Normal and Bcr-Abl-Expressing Hematopoietic Progenitors. Mol Cell Biol 2004, 24:6172-6183. 10.1128/MCB.24.14.6172-6183.2004, 434248, 15226421.
47. Aichberger KJ, Mayerhofer M, Krauth M-T, Vales A, Kondo R, Derdak S, Pickl WF, Selzer E, Deininger M, Druker BJ, et al. Low-Level Expression of Proapoptotic Bcl-2-Interacting Mediator in Leukemic Cells in Patients with Chronic Myeloid Leukemia: Role of BCR/ABL, Characterization of Underlying Signaling Pathways, and Reexpression by Novel Pharmacologic Compounds. Cancer Res 2005, 65:9436-9444. 10.1158/0008-5472.CAN-05-0972, 16230407.
48. Kuroda J, Puthalakath H, Cragg MS, Kelly PN, Bouillet P, Huang DCS, Kimura S, Ottmann OG, Druker BJ, Villunger A, et al. Bim and Bad mediate imatinib-induced killing of Bcr/Abl+ leukemic cells, and resistance due to their loss is overcome by a BH3 mimetic. Proc Natl Acad Sci USA 2006, 103:14907-14912. 10.1073/pnas.0606176103, 1595449, 16997913.
49. Nordigarden A, Kraft M, Eliasson P, Labi V, Lam EWF, Villunger A, Jonsson J-I. BH3-only protein Bim more critical than Puma in tyrosine kinase inhibitor-induced apoptosis of human leukemic cells and transduced hematopoietic progenitors carrying oncogenic FLT3. Blood 2009, 113:2302-2311. 10.1182/blood-2008-07-167023, 19064725.
50. Dai Y, Grant S. Targeting Multiple Arms of the Apoptotic Regulatory Machinery. Cancer Res 2007, 67:2908-2911. 10.1158/0008-5472.CAN-07-0082, 17409392.
51. Opferman JT, Letai A, Beard C, Sorcinelli MD, Ong CC, Korsmeyer SJ. Development and maintenance of B and T lymphocytes requires antiapoptotic MCL-1. Nature 2003, 426:671-676. 10.1038/nature02067, 14668867.
52. James C, Ugo V, Le Couedic J-P, Staerk J, Delhommeau F, Lacout C, Garcon L, Raslova H, Berger R, Bennaceur-Griscelli A, et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 2005, 434:1144-1148. 10.1038/nature03546, 15793561.
53. Wernig G, Kharas MG, Okabe R, Moore SA, Leeman DS, Cullen DE, Gozo M, McDowell EP, Levine RL, Doukas J, et al. Efficacy of TG101348, a Selective JAK2 Inhibitor, in Treatment of a Murine Model of JAK2V617F-Induced Polycythemia Vera. Cancer Cell 2008, 13:311-320. 10.1016/j.ccr.2008.02.009, 18394554.
54. Pikman Y, Lee BH, Mercher T, McDowell E, Ebert BL, Gozo M, Cuker A, Wernig G, Moore S, Galinsky I, et al. MPLW515L Is a Novel Somatic Activating Mutation in Myelofibrosis with Myeloid Metaplasia. PLoS Med 2006, 3:e270. 10.1371/journal.pmed.0030270, 1502153, 16834459.
55. Verstovsek S. Therapeutic Potential of Janus-activated Kinase-2 Inhibitors for the Management of Myelofibrosis. Clin Cancer Res 2010, 16:1988-1996. 10.1158/1078-0432.CCR-09-2836, 20215535.
56. Lessene G, Czabotar PE, Colman PM. BCL-2 family antagonists for cancer therapy. Nat Rev Drug Discov 2008, 7:989-1000. 10.1038/nrd2658, 19043450.